Health Canada authorizes injection for treatment of adult patients with type 2 diabetes
Health Canada has authorised the first generic version of semaglutide in Canada and across the G7, a move that could lower costs for employer‑sponsored drug plans that cover type 2 diabetes treatments commonly used by working‑age Canadians.
In a recent decision, the regulator approved a generic semaglutide injection from Dr. Reddy’s Laboratories “for the once-weekly treatment of adult patients with type 2 diabetes to manage blood sugar levels.” The product is a generic equivalent of Ozempic, marketed in Canada by Novo Nordisk.
Semaglutide is a long‑acting glucagon‑like peptide‑1 (GLP‑1) receptor agonist – a synthetic analogue of the natural GLP‑1 hormone that binds to and activates the GLP‑1 receptor.
“Today, Health Canada authorized a generic semaglutide injection. This is the first generic semaglutide authorized by Health Canada, and the first to be approved in the G7,” the department said in its news release. Health Canada added that it is “currently reviewing eight other submissions for generic semaglutide by different companies” and expects to make additional regulatory decisions “in the coming weeks and months.”
The regulator said its review ensures that differences between the generic products and the reference biologic “do not affect the safety, efficacy, or quality of the drug.” It added that the availability of generic drugs “is expected to have a positive impact in Canada, including potential cost savings for patients and the healthcare system,” and that many generic medicines in Canada are 45% to 90% cheaper than their brand‑name counterparts.
Expert warns of 'benefits' of Ozempic
One expert claims that it makes economic sense to include generic GLP‑1 drugs in insurance plans.
“I think it will overall benefit the health system with reducing costs related to obesity treatment, cardiovascular disease,” said Dana Small, a neurology and neurosurgery professor at McGill University, according to a report from Global News. “I think the cost-benefit analysis will come out that there is a net gain because of the prevention of all the chronic diseases in the hospital and care costs associated with that.”
However, Small also urged caution for those thinking of going on the drugs.
“It depends on each person, and once you start taking the drugs, you can lose a lot of weight. You can really improve glucose control. But the moment you stop taking it, everything goes back to the way it was,” she said. “So, it’s something that you need to stay on it in order to continue with the benefits.”
Stopping or interrupting treatment with GLP-1 medications — commonly used for weight loss and for treating diabetes — has been linked to a significant increase in risk for major cardiovascular events, according to recent research.
How does semaglutide work?
Here’s how semaglutide works, according to Canadian government sources:
|
Where it acts / mechanism |
What semaglutide does (mechanism of action) |
Why it matters clinically |
Canadian authority citing this mechanism* |
|
GLP‑1 receptor (overall) |
Semaglutide is a GLP‑1 receptor agonist (GLP‑1 analogue) that binds to and activates the GLP‑1 receptor, mimicking the action of natural GLP‑1 released after a meal. |
Activating the GLP‑1 receptor drives a coordinated response that lowers blood glucose and supports weight loss, making it useful in type 2 diabetes management. |
Health Canada product monographs (e.g., Ozempic, Wegovy) describe semaglutide as a “glucagon‑like peptide‑1 (GLP‑1) receptor agonist” used for type 2 diabetes and weight management |
|
Pancreatic beta cells (insulin) |
When blood glucose is elevated, semaglutide enhances glucose‑dependent insulin secretion from pancreatic beta cells via GLP‑1 receptor activation. |
More insulin is released only when glucose is high, which lowers blood sugar with a lower risk of hypoglycaemia compared with drugs that stimulate insulin regardless of glucose level. |
Canadian clinical guidance for GLP‑1 receptor agonists (including semaglutide) notes they “increase glucose‑dependent insulin secretion” in type 2 diabetes |
|
Pancreatic alpha cells (glucagon) |
Semaglutide suppresses inappropriate glucagon secretion from pancreatic alpha cells when glucose is high. |
Lower glucagon reduces hepatic (liver) glucose output, contributing to improved fasting and post‑meal blood glucose control. |
Canadian endocrinology and diabetes overviews of GLP‑1 RAs state they “reduce inappropriately elevated glucagon” as a key mechanism for lowering blood glucose in type 2 diabetes |
|
Stomach / gut (gastric emptying) |
Semaglutide slows gastric emptying through GLP‑1 receptor action in the gastrointestinal tract. |
Food moves more slowly from the stomach to the intestine, which blunts post‑meal (post‑prandial) glucose spikes and improves satiety. |
Health Canada labelling for GLP‑1 RAs used in Canada (including semaglutide) notes delayed gastric emptying as a mechanism affecting post‑prandial glycaemia |
|
Brain (appetite and satiety) |
In the brain, semaglutide activates GLP‑1 receptors in appetite‑regulation centres, increasing satiety and reducing appetite. |
Patients tend to eat less and feel full sooner, which reduces caloric intake and supports clinically meaningful weight loss, particularly relevant where obesity and type 2 diabetes coexist. |
Canadian obesity and diabetes guidance describing GLP‑1 RAs (including semaglutide) highlight central appetite effects leading to “reduced energy intake and weight loss” |
|
Overall glucose control |
By combining increased insulin (when glucose is high), reduced glucagon, slower gastric emptying and reduced intake, semaglutide lowers fasting and post‑meal blood glucose and improves HbA1c. |
Better glycaemic control reduces risk of diabetes complications (e.g., cardiovascular, kidney and eye disease), which can lower long‑term health and disability costs for employers. |
Health Canada‑authorised Product Monographs for semaglutide list improved HbA1c and fasting/post‑prandial glucose as primary efficacy outcomes in type 2 diabetes |
|
Body weight / cardiometabolic risk |
Through reduced appetite and energy intake, semaglutide leads to clinically significant weight loss, particularly at obesity‑indicated doses. |
Weight reduction can improve blood pressure, lipids and glycaemic control, potentially lowering cardiometabolic risk and related claims over time. |
Health Canada approvals of higher‑dose semaglutide for weight management, together with Canadian obesity guidelines, describe sustained weight loss via GLP‑1–mediated appetite reduction and energy‑intake lowering |
Federal priorities: pharmaceuticals and affordability
The semaglutide approval coincides with Health Canada’s 2026‑27 Departmental Plan, which identifies “improving the accessibility, affordability, and timeliness of pharmaceuticals for Canadians” as one of the department’s key priorities for the coming year.
As part of this work, Health Canada plans to fund Canada’s Drug Agency to conduct health technology assessments, advance appropriate‑use strategies for prescription drugs and “bring new medications to Canadians faster” by aligning regulatory approvals and reimbursement recommendations. The department’s plan states that it will work toward issuing regulatory approval of a drug and public‑plan recommendations “on the same day” for participating jurisdictions.
The plan also highlights targeted measures for diabetes and related therapies. Under national pharmacare bilateral agreements, Health Canada will support British Columbia, Manitoba, Prince Edward Island and Yukon in providing free or low‑cost contraception and diabetes medications through initiatives such as the Diabetes Devices and Supplies Fund and the Universal Access to Contraception and Diabetes Medications Initiative.
Health Canada’s performance framework replaces older indicators tied to overall national drug spending with a new measure of pharmaceutical spending per capita, projected to fall between $1,212 and $1,340 by 2026‑27. The department links this metric to its broader objective of modern and sustainable health care systems, including efforts to reduce cost‑related non‑adherence to prescription medicines.
Within its “health care systems” core responsibility, Health Canada has set total planned spending of about $9.8 billion in 2026‑27, out of an overall departmental budget of approximately $11.0 billion. The plan ties this spending to work on prescription pharmaceuticals, health workforce measures, digital health and oral health care.
In Canada, GLP-1 medications are already a significant driver of drug plan spending — an Alberta Blue Cross report that reviewed new drug and supplemental submissions made to Health Canada in 2025 named such treatments as a major cost of employer-sponsored drug plans, particularly as the drugs are approved for treatment of more conditions.
Regulatory modernisation and review performance
Health Canada positions the semaglutide decision within a broader agenda of regulatory modernisation. One of its 2026‑27 priorities is “enabling modern, risk-based regulatory processes while ensuring that health and safety are not compromised,” particularly in areas such as pharmaceuticals and clinical trials.
The department said it completed the scientific review of Dr. Reddy’s generic semaglutide submission within its 180‑day target timeline for generic drug files, excluding the time taken by the manufacturer to respond to requests for additional data. It stated that its review target “for generic drug submissions is shorter than many international regulators,” reflecting a goal of maintaining timely access to medicines.
In its Departmental Plan, Health Canada commits to “proposing regulatory amendments to enable more innovation in drug clinical trials and make Canada a more attractive place for companies to invest.” It also plans to introduce amendments aimed at improving predictability for regulated parties and streamlining authorisation processes for health products, while maintaining safety, effectiveness and quality standards.
